SCHEMBL2357914

SCHEMBL2357914

CC(C)n1cnc2c(NCCc3cnc4[nH]ccc4c3)nc(-c3cccnc3)nc21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AHR P35869 1/20 0.46
▸ CDK2 P24941 8/20 0.44
▸ CDK9 P50750 3/20 0.44
▸ CDK1 P06493 8/20 0.44
▸ CCNE1 P24864 6/20 0.44
▸ CCNB1 P14635 6/20 0.44
▸ CDK4 P11802 5/20 0.44
▸ MAPK1 P28482 5/20 0.44
▸ CDK7 P50613 5/20 0.44
▸ CCNH P51946 4/20 0.44
▸ CDK5 Q00535 4/20 0.44
▸ CCND1 P24385 3/20 0.44
▸ CCNT1 O60563 2/20 0.44
▸ MNAT1 P51948 1/20 0.44
▸ CDK6 Q00534 1/20 0.44
▸ CCNK O75909 7/20 0.44
▸ CDK12 Q9NYV4 7/20 0.44
▸ CCNE2 O96020 2/20 0.43
▸ CCNA2 P20248 2/20 0.43
▸ CCNA1 P78396 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21240860 0.97 AHR (0.45) AHRCDK2CDK9CDK1CCNE1
SCHEMBL15684650 0.89 CCNK (0.47) AHRCDK2CDK9CDK1CCNE1
SCHEMBL21016907 0.88 AHR (0.44) AHRCDK2CDK9CDK1CCNE1
SCHEMBL2318356 0.85 AHR (0.51) AHRCDK2CDK9CDK1CCNE1
SCHEMBL15010781 0.83 CCNK (0.38) AHRCDK2CDK9CDK1CCNE1
SCHEMBL13282111 0.83 AHR (0.46) AHRCDK2CDK9CDK1CCNE1
SCHEMBL2358541 0.83 CCNK (0.52) AHRCDK2CDK9CDK1CCNE1
SCHEMBL20895840 0.83 AHR (0.49) AHRCDK2CDK9CDK1CCNE1
SCHEMBL2317564 0.83 AHR (0.62) AHRCDK2CDK9CDK1CCNE1
SCHEMBL3501809 0.82 AHR (0.51) AHRCDK2CDK9CDK1CCNE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210187033-A1 COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS NOVARTIS AG (CH) 2021-06-24 — — US claimed
US-20170239296-A1 COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS NOVARTIS AG (CH) 2017-08-24 — — US claimed
US-9580426-B2 Compounds that expand hematopoietic stem cells NOVARTIS AG (CH) 2017-02-28 — — US claimed
US-9175266-B2 Enhancement of natural killer (NK) cell proliferation and activity GAMIDA CELL LTD. (IL) 2015-11-03 — — US claimed
US-8927281-B2 Method for expanding hematopoietic stem cells IRM LLC (BM) 2015-01-06 — — US claimed
US-20140114070-A1 COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS THE SCRIPPS RESEARCH INSTITUTE (US) 2014-04-24 — — US claimed
US-20140023626-A1 Enhancement of Natural Killer (NK) Cell Proliferation and Activity GAMIDA CELL INC. 2014-01-23 — — US claimed
US-20140023623-A1 Methods of Culturing and Expanding Mesenchymal Stem Cells and Isolated Cell Populations Generated Thereby GAMIDA CELL INC. 2014-01-23 — — US claimed
CN-102203096-A Compounds that expand hematopoietic stem cells IRM LLC 2011-09-28 — — CN claimed
EP-2350078-A2 COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS IRM LLC (BM) 2011-08-03 — — EP claimed
US-20100183564-A1 COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS IRM LLC (BM) 2010-07-22 — — US claimed
WO-2010059401-A2 COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS IRM LLC (BM) 2010-05-27 — — WO claimed
EP-3524604-B1 EXPANDED HEMATOPOIETIC STEM CELLS FROM CORD BLOOD AND THEIR THERAPEUTIC USE NOVARTIS AG (CH) 2023-03-29 — — EP disclosed
US-20210187033-A1 COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS NOVARTIS AG (CH) 2021-06-24 — — US disclosed
US-20210187033-A1 COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS NOVARTIS AG (CH) 2021-06-24 — — US disclosed
EP-3524604-A1 EXPANDED HEMATOPOIETIC STEM CELLS FROM CORD BLOOD AND THEIR THERAPEUTIC USE Novartis AG (CH) 2019-08-14 — — EP disclosed
US-20100183564-A1 COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS IRM LLC (BM) 2010-07-22 — — US disclosed
US-20100183564-A1 COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS IRM LLC (BM) 2010-07-22 — — US disclosed
WO-2010059401-A2 COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS IRM LLC (BM) 2010-05-27 — — WO disclosed
WO-2010059401-A2 COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS IRM LLC (BM) 2010-05-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170239296-A1 COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS CD47, HCLS1, CD74 AHR 525/4885CDK2 3659/4885CDK9 2731/4885
US-20210187033-A1 COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS CD47, HCLS1, CD74 AHR 525/4885CDK2 3659/4885CDK9 2731/4885
US-20140114070-A1 COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS CD47, HCLS1, CD74 AHR 525/4885CDK2 3659/4885CDK9 2731/4885
US-20140023626-A1 Enhancement of Natural Killer (NK) Cell Proliferation and Activity PBK, IL2, AHR AHR 3/4885CDK2 1909/4885CDK9 668/4885
US-20100183564-A1 COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS CD47, HCLS1, CD74 AHR 525/4885CDK2 3659/4885CDK9 2731/4885
US-20140023623-A1 Methods of Culturing and Expanding Mesenchymal Stem Cells and Isolated Cell Populations Generated Thereby AHR, HGF, MTNR1A AHR 1/4885CDK2 2032/4885CDK9 3685/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback